Peptide Business in Indonesia: What’s Legal in 2026

Is a Peptide Business Legal in Indonesia?

Interest in peptides is growing across healthcare, medical aesthetics, wellness and skincare. For foreign investors, Indonesia may offer opportunities in regulated pharmaceutical products, specialist healthcare services and peptide-based cosmetics. However, the commercial opportunity depends on the specific peptide, its intended use and the regulatory approvals required.

There is no single Indonesian regulatory category for all peptides. A peptide marketed as a prescription medicine, an ingredient in topical skincare and an oral health supplement may be subject to different requirements.

Indonesia’s principal regulatory authorities include the National Agency of Drug and Food Control (BPOM), the Ministry of Health and the Halal Product Assurance Organizing Agency (BPJPH). Investors must establish the correct regulatory pathway before importing, marketing or administering a peptide product.

The key distinction is between a lawful, regulated peptide business and the sale or administration of products that lack the required authorisations.

1. How Does Indonesia Regulate Peptides?

Peptides are short chains of amino acids. Their regulatory classification depends on the formulation, route of administration, intended purpose, claims and applicable product standards.

These categories are not interchangeable. An injectable product cannot be treated as a cosmetic simply by changing its label, and describing a product as “for research use only” does not automatically make its commercial supply lawful.

What about BPC-157, TB-500, CJC-1295 and Ipamorelin?

These compounds require particular caution. Investors should not assume that a product is authorised for human use in Indonesia because it is available from an overseas supplier or advertised by a wellness clinic.

Before committing capital, verify each product’s Indonesian registration status, permitted indication and import eligibility. Foreign approval, where it exists, does not automatically confer Indonesian marketing authorisation.

The same verification is necessary for semaglutide products and other commercially established medicines. Registration should be checked against the exact product, formulation and authorisation holder in BPOM’s official database.

2. Four Potentially Lawful Peptide Business Routes

Route 1: Establish a Specialist Healthcare Clinic

Investors may explore a properly licensed healthcare facility that provides medical services using medicines authorised for use in Indonesia.

A clinic’s business licence, clinical scope, professional staffing and operating approvals must match its actual activities. Foreign investors should verify the appropriate business classification under the current Indonesian Standard Industrial Classification (KBLI), foreign investment restrictions and Ministry of Health requirements before choosing a company structure.

For prescription peptide medicines, the clinic must follow applicable prescribing, procurement, storage, dispensing and patient-safety requirements. Products should be sourced through authorised channels.

This route may suit investors targeting regulated medical care, including weight-management or other specialist services, provided the chosen medicines are authorised for the intended use and the clinic is appropriately licensed.

Important: A clinic licence does not authorise the use of every peptide, and a prescription does not replace a product’s required regulatory approvals.

Route 2: Explore Healthcare Investment in KEK Sanur

Bali’s Sanur Special Economic Zone (Kawasan Ekonomi Khusus or KEK Sanur) has a regulatory mechanism that may permit eligible healthcare facilities to access certain medicines not registered through the ordinary Indonesian marketing-authorisation route.

BPOM Regulation No. 30 of 2022, as amended by BPOM Regulation No. 12 of 2024, governs the Special Access Scheme (SAS) for the importation of medicines and medicinal substances. BPOM has specifically discussed the implementation of this mechanism for healthcare services in KEK Sanur. Official BPOM regulation and BPOM’s KEK Sanur guidance.

However, SAS is a controlled access mechanism, not a general import licence or a way to create an unrestricted market for unregistered products. Eligibility, the applicant, the medicine, the intended patients and the permitted use must satisfy the applicable requirements.

For investors, this means KEK Sanur may justify further regulatory due diligence, but it should not be treated as a guaranteed route for BPC-157, TB-500 or other unregistered peptides. Whether a particular synthetic peptide qualifies must be confirmed with the relevant authorities before a business plan relies on it.

Route 3: Launch Peptide-Based Skincare or Collagen Supplements

Topical skincare and oral collagen products may provide a more accessible consumer-market opportunity, depending on their formulation and claims.

For cosmetics, investors must assess the ingredients, product safety, labelling and BPOM notification requirements. Claims should remain within the permitted cosmetic scope. Claims to treat disease or deliver pharmaceutical effects can trigger a different regulatory assessment.

Oral collagen-peptide supplements must satisfy the applicable health supplement registration, ingredient and labelling rules. Registration of one product does not automatically cover a different formulation or brand.

Indonesia’s halal certification requirements also require advance planning. Under Government Regulation No. 42 of 2024, the phase-in period for halal certification ends on 17 October 2026 for cosmetics and health supplements, while prescription medicines (excluding psychotropic medicines) have a later deadline of 17 October 2034. Investors should verify the specific requirements and applicable deadlines for their products and business categories with the Indonesian Halal Product Assurance Agency (BPJPH). Government Regulation No. 42 of 2024

This route may suit investors seeking to develop a consumer brand, work with a qualified contract manufacturer or appoint an Indonesian importer and distributor.

Route 4: Register and Commercialise a Peptide Medicine

Investors with pharmaceutical-sector experience and sufficient funding may consider obtaining Indonesian marketing authorisation for a medicine through the applicable registration process.

The project may involve an eligible Indonesian registration holder, manufacturing and quality documentation, evidence of safety and efficacy, product-specific technical data and compliant import or distribution arrangements.

Where a new medicine requires clinical research, the relevant clinical trial approvals must be addressed before the trial begins. Registration timelines, costs and evidence requirements depend on the product and its development status.

This route generally requires more time and capital than launching a compliant cosmetic product. It is best suited to investors with pharmaceutical partners, access to reliable product data and a long-term commercial strategy.

3. What Are the Risks of Selling Unregistered Peptides?

Indonesia’s Health Law No. 17 of 2023 establishes requirements for pharmaceutical product safety, quality, efficacy and lawful distribution. Article 435 provides criminal penalties of up to 12 years’ imprisonment or a fine of up to IDR 5 billion for the specified offence involving pharmaceutical preparations that fail to meet applicable safety, efficacy and quality requirements.

The precise offence and penalties depend on the facts and the applicable statutory provisions. Investors should not interpret Article 435 as imposing the same penalty automatically on every product that lacks registration.

Other potential compliance issues include unauthorised pharmaceutical practice, unlawful imports, improper distribution, misleading product claims and breaches of professional or facility licensing requirements.

Common risk areas include:

• Online sales from overseas: An offshore company does not automatically exempt products shipped to Indonesian customers from Indonesian import and product regulations.
• Research-use-only labelling: A disclaimer does not, by itself, establish that a product’s actual supply and intended use are lawful.
• Unregistered injectable products: A wellness or aesthetic clinic cannot assume that its operating licence authorises the use of an unregistered medicine.
• Misclassification: Calling an injectable medicine a cosmetic or supplement does not determine its legal status.

Investors should assess these risks before signing supplier agreements, marketing products or accepting customer payments.

4. Key Regulations for Peptide Investors in Indonesia

The applicable requirements depend on the product and business model. Investors should confirm whether additional rules on clinical trials, pharmaceutical distribution, cosmetics, supplements, foreign investment or healthcare facilities apply.

5. How Should Foreign Investors Enter the Indonesian Peptide Market?

A compliant market-entry strategy should begin with product classification, not company incorporation.

First, prepare a product inventory. Identify every peptide, manufacturer, formulation, route of administration, proposed indication and target customer. Separate registered medicines from cosmetics, supplements, investigational products and compounds whose Indonesian regulatory status remains unresolved.

Second, verify the regulatory position. Search the official BPOM product database and obtain documentary evidence of relevant registrations. Where a product is not registered, determine whether any specific lawful access or research pathway is available. Do not assume foreign approval is sufficient.

Third, select the appropriate business model. A healthcare clinic, cosmetic brand, supplement distributor and pharmaceutical registration business have different licensing, staffing, capital and compliance requirements. Foreign investors should also verify the applicable foreign ownership rules and current OSS requirements for the chosen KBLI.

Fourth, obtain written regulatory clarification where necessary. For a proposed KEK Sanur project, consult the zone operator and relevant authorities regarding facility eligibility, medicine access, permitted use and operational conditions. Do this before committing to a lease or making revenue projections based on SAS access.

Finally, implement compliance controls. These should cover supplier due diligence, product registration, import documentation, storage, advertising claims, prescription procedures where applicable, adverse-event reporting and ongoing regulatory monitoring.

6. Which Peptide Business Model Offers the Best Opportunity?

There is no single best route for every investor.

For investors seeking a relatively straightforward entry, compliant peptide-based skincare or eligible collagen supplements may be worth evaluating first. Investors seeking to provide medical treatment should focus on an appropriately licensed clinic using authorised products. Pharmaceutical registration may suit investors with established industry partners and greater resources.

KEK Sanur deserves separate investigation where access to certain unregistered medicines is commercially important, but approval must be established for the specific proposed product and use.

Build a Peptide Business on a Compliant Regulatory Pathway

Indonesia offers several potential business routes for peptide-related products and healthcare services. However, the legal feasibility of each project depends on product classification, Indonesian authorisation requirements, import rules and the proposed commercial activities.

The most important principle is that a company structure, overseas supplier or special economic zone does not automatically make an otherwise unauthorised product lawful to sell or administer.

Before investing, verify the status of each product, confirm the applicable licences and obtain regulatory advice on any unresolved questions. A properly structured market-entry plan can help investors identify viable opportunities while reducing exposure to regulatory, financial and reputational risks.

How ILA Global Consulting can help

ILA Global Consulting assists international investors with Indonesian market entry, corporate structuring, regulatory due diligence and business licensing. For a proposed peptide venture, our team can help assess the business model, identify regulatory questions requiring confirmation and coordinate the legal and corporate work needed to establish a compliant operation.

Planning a clinic, skincare brand or health product in Indonesia? We map your product list to the right route, set up the PT PMA and licences, and coordinate with Indonesian counsel on BPOM questions.

Talk to Our Team

This article provides general information based on the regulatory framework reviewed as of 13 October 2026. It is not a product-specific BPOM determination or a substitute for legal advice. Regulatory status and licensing requirements should be reconfirmed before investment or commercial launch.